OrthoPediatrics (NASDAQ: KIDS) details 2025 growth and 2026 outlook
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
OrthoPediatrics Corp. furnished an investor presentation outlining its 2025 performance and 2026 outlook. For 2025, revenue reached
The presentation highlights long-term double-digit revenue growth, a broad pediatric-focused product portfolio and contributions from acquisitions such as Boston Orthotics & Prosthetics. Management’s 2026 guidance targets revenue of
Positive
- Accelerating scale with improving economics: 2025 revenue grew 15% to
$236.3 million while Adjusted EBITDA rose to$14.8 million and free cash flow usage improved to$15 million from$42 million , with 2026 guidance targeting$262.0 –$266.0 million revenue, ~$25 million Adjusted EBITDA and breakeven free cash flow.
Negative
- None.
Insights
OrthoPediatrics pairs strong revenue growth with a clear 2026 profitability and cash-flow improvement target.
OrthoPediatrics shows sustained expansion, with 2025 revenue of
Despite this, the company remains loss-making, with a 2025 net loss of
Guidance for
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
______________________
Date of Report (Date of earliest event reported): February 26, 2026
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation) | ||
| (Commission File Number) | (I.R.S. Employer Identification Number) | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
Registrant’s telephone number, including area code: (574 ) 268-6379
| Not Applicable | ||
| (Former name or former address, if changed since last report) | ||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨
Item 7.01. Regulation FD Disclosure.
The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.
The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits | |||||||
| Exhibit No. | Description | |||||||
99.1 | OrthoPediatrics Corp. Investor Presentation dated February 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
* * * * * *
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OrthoPediatrics Corp. | ||||||||
| Date: February 26, 2026 | By: | /s/ Daniel J. Gerritzen | ||||||
| Daniel J. Gerritzen, General Counsel and Secretary | ||||||||
- 2 -
2026 Investor Presentation www.OrthoPediatrics.com
22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements speak only as of the date of this report. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others; We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in our quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 5, 2025, and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report. Use of Non-GAAP Financial Measures This press release includes certain non-GAAP financial measures such as adjusted diluted loss per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, plus the accreted interest attributable to acquisition installment payables, restructuring charges, European Union Medical Device Regulation fees, acquisition related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense, provision for income taxes (benefit), depreciation and amortization, stock-based compensation expense, restructuring charges, European Union Medical Device Regulation fees, acquisition related costs, and the cost of minimum purchase commitments. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of reported GAAP diluted loss per share to non-GAAP diluted loss and net loss to non-GAAP Adjusted EBITDA. Disclaimer
32 0 2 6 / / pediatric patients treated since inception + 1,291,000 OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions 1 1 Includes patients treated by MD Orthopaedics (MDO), Pega Medical (Pega), and Boston Orthotics & Prosthetics (Boston O&P) since inception
01 Children’s unique clinical conditions Existing solutions are re-purposed from adult implants Limited development of new technologies No specialized sales force in Pediatric Orthopedics Limited industry support of clinical education 02 03 04 05 42 0 2 6 / / Historical Challenges of Pediatric Orthopedics Re-Purposed Adult Plate Screws through growth plate
52 0 2 6 / / OrthoPediatrics Solution 01 02 03 04 05 Product development focused exclusively on pediatric patients Broadest pediatric specific portfolio in the industry Delivering first in market novel surgical solutions Only global commercial channel to market Leading provider of surgeon clinical education PediLoc Femur Screws parallel to growth plate Enhance surgeon confidence Increase surgical efficiency Improve surgical accuracy
62 0 2 6 / / Only Focused Pediatric Orthopedic Company Consistent YoY Growth Since Inception 1 Excluding COVID-impacted 2020 +85 unique pediatric systems Consistent cadence of innovative product launches Expanding suite of enabling technologies Internal R&D, acquisitions, and partnerships Only global sales & distribution channel Serve 100% of top children’s hospitals in the U.S. ~230 domestic field representatives Sell in over 75 countries around the world Commitment to clinical education Leading sponsor of critical pediatric medical societies >300 clinical product/education events per year Founder of Foundation of Advancing Pediatric Orthopedics Innovative Technology Commercial Execution Clinical Education 1
72 0 2 6 / / Total Global Addressable Market – $6.2B Competitive Dynamics $610M Trauma & Deformity Correction Implants $340M Scoliosis Fusion Impants $80M Scoliosis Non- Fusion Implants $60 EOS Implants $775M Specialty Bracing $250M Sports Medicine Implants $165M Growing Implants $500 Enabling Technology Large incumbents repurpose adult implants Require specialized sales force Lack of focus on pediatric conditions 01 02 03 U.S. Addressable Market1 — $2.8B 2 0 2 6 / / 1 Management’s Estimate as of January 2025 updates to IMS data from 2016
82 0 2 6 / / Strategic Pillars 02 Provide a broad product portfolio uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs 04 Expand addressable market through aggressive investment in R&D and select M&A opportunities 05 Train next generation of pediatric orthopedic surgeons 03 Deploy instrument sets and provide unparalleled sales support 01 Laser focus on high-volume Children’s Hospitals that treat majority of pediatric patients
92 0 2 6 / / Comments ~1,520 Fellowship Trained Pediatric Surgeons Majority of Pediatric Centers are Teaching Hospitals Centers Treat Most Complex Pediatric Conditions ~80% of Pediatric Surgeons time is Non-Surgical 01 02 03 01 Focus on High-Vol Children’s Hospitals Current US Target Market – $1.6B 04 1 Management’s Estimate as of January 2025 updates to IMS data from 2016 $455M Trauma, Deformity Correction & Sports Medicine Implants $330M Scoliosis Fusion & Non-Fusion Implants $500M Specialty Bracing $300M Enabling Tech Current U.S. Target Market1 — $1.6B
102 0 2 6 / / Pre-IPO Transitioned from Early Entry to Clinically Significant Cannulated Screws Response 5.5/6.0mm Fusion System PediPlate Physeal Tethering Hip Systems LCB / LPF ACL System BandLoc 5.5/6.0mm Banding Clavicle Plating System PediFlexPediLoc Femur PediLoc Tibia PediFragLocking Proximal Femur LPF Plate Distal Femoral Osteotomy System DFOS PAOSpica Table 02 Broad Product Portfolio 2008 2009 PediNail System 2012 2013 2014 2015 2016 2017
112 0 2 6 / / Accelerating Sales Growth Post-IPO Through Strategic Investment and Innovation $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Total Revenue ($M) CAGR20252016 11%23290U.S. Independent Sales Consultants 10%$17$7MInstrument Set Deployments 20%8717Unique Pediatric Systems Fav160Intl. Independent Sales Agencies Increase Hospital PenetrationAccelerate Revenue Growth Improve Profitability Leverage Balance Sheet +20% CAGR 03 Expand Instr. Sets & Sales Personnel 1 1 Impacted by COVID
122 0 2 6 / / Post-IPO moved from Clinically Significant to Disruptive 20202019 20252018 2021 PNP Pediatric Nailing Platform Response 4.5/5.0mm Fusion System Orthex External Fixation Systems PediFoot System SCFE System QuickPack System ApiFix Non-Fusion Neuromuscular Scoliosis System 7D Intraoperative Navigation Enabling Technology 04 Expand Market with R&D Mini Rail System 2022 MD Ortho PonsetiTM Specialty Clubfoot Bracing PediFlexTM Advanced Interlock Clamp System Drive Rail External Fixation System Pega FD Telescopic IM Nail System 2023 MDO Move Brace Scoliosis Cannulated Screw System RESPONSE Power System GIRO System Developed by Pega DF2 Brace MP+ Bar PNP Tibia System 2024 RESPONSE Rib & Pelvic Fixation System Levity Device For Gait Playbook Iota Motion Robot Bracing Compliance Sensor MOVE-D Brace Rigid Brace X-Glide Carbon Fiber Insole TruStretch Pediatric Equinus Brace Verteglide F3 Hero Pediatric AFO 3P Small-Mini & Hip Modular Abduction System
132 0 2 6 / / Strategic Acquisitions & Partnerships Partnership Acquisition 202020192017 2022 04 Expand Market with M&A 2021 2023 2024
142 0 2 6 / / Acquired Innovative Technologies Boston Orthotics & Prosthetics • Pioneered the original patient-specific, custom Boston Scoliosis Brace • Currently has 5 disease state focuses with 17 different product offerings • Custom manufacturing and fabrication center based outside of Boston, MA • Newly established headquarters for the OrthoPediatrics Specialty Bracing (OPSB) division • Owns and operates 26 pediatric / adolescent focused O&P clinics (w/CPOs) in 10 states, mainly New England area Terms: • Closed January 5, 2024 • $22M Cash 04 Expand Market with M&A State-of-the-Art Products - - That Better Each Patient’s Life
152 0 2 6 / / Comments ~80% of Pediatric Surgeons Time is Non-Surgical Same Surgeons Who Use OP Surgical Products Relationship with OP Sales Channel Surrounds the Surgeon with all the Products They Need 01 02 03 $200M Lower Limb Extremity Specialty Bracing $125M Hip / Cranial / Other Speciality Bracing $175M Scoliosis Speciality Bracing 300 U.S. Pediatric Centers U.S. Specialty Bracing Market 1 — $0.5B Current Global Target Market – $1.1B 2 0 2 6 / / 04 1 Management’s Estimate as of January 2025 04 Expand Market with M&A
162 0 2 6 / / Motion Assist Devices Fracture Fixation Devices Specialty Casting Spine Halo Traction, Other Specialty Solutions 300 U.S. Pediatric Centers U.S. Potential Target Market 1 — $1.0B Potential Global Target Market – $2.2B 2 0 2 5 / / 1 Management’s Estimate as of January 2025 Levity Device for Gait Assist Dynamic Femur Fracture (DF2) Brace 04 Expand Market with M&A
172 0 2 6 / / PLAYBOOK Workflow & Care Optimization for the OR DIGITAL WORK INSTRUCTIONS define best practices for each user’s role throughout the entire surgical procedure DATA ANALYTICS Surgical Debrief provides real-time PERFORMANCE VISUALIZATION metrics INTERACTIVE LIVE SURGERY VIEW for remote support, education and training DYNAMIC PRE-OP PLANNING offers coordination and communication across CPD, Rep and Care Team REAL-TIME SURGEON PREF CARD UPDATES with notifications to drive accountability for changes QUALITY CHECKLISTS are initiated based on surgery phase and step completion Better care requires improved planning, communication & support to deliver reproducible outcomes 04 Expand Market with M&A Acquired Innovative Technologies
182 0 2 6 / / ApiFix • Disruptive non-fusion technology • Viable alternative to failed bracing & spinal fusion • Posterior, minimally invasive approach • Motion preserving capabilities • Granted FDA HDE approval Orthex • Disruptive software complements ex-fix frame • Expands addressable market • Serve 85% of procedures, up from 65% • Significantly simplifies surgical planning and alignment • Enables participation in most complex surgeries Acquired software-based and non-fusion technologies Significant sales synergies with legacy portfolio Expands critical KOL network Provides surgeons broadest product portfolio Acquired Innovative Technologies04 Expand Market with M&A
192 0 2 6 / / FIREFLY® Pedicle Screw Navigation Guides FireFly S2/Alar Unique patient specific 3D printed bone models and drill guides, can be used with any Spinal Deformity Correction system. • 99.7% screw placement accuracy • Preoperative concierge surgical planning drives intraoperative efficiency • Minimal intraoperative radiation • Simplifies S2AI approach Enabling Technology Partnerships 7D Surgical Intraoperative Navigation Eliminates Radiation exposure to staff & patients Cuts Registration from 30 min to < 30 sec Improves Accuracy to improve surgical outcomes Reduces Costs & improve hospital economic value 04 Expand Market with M&A
202 0 2 6 / / Physician Education and Awareness OP Hands-on sales training and support • Annually invests 3% of sales on clinical education • Conducts >300 product/training sessions per year Continuous education • Major Sponsor of the prominent pediatric orthopedic societies Market development • Fosters early relationships with young surgeons and fellows to drive sustainable growth 02 03 01 As a surgeon educator, I have always appreciated and valued OrthoPediatrics’ commitment to education. Ryan Goodwin, MD, MBA, FAOA The Cleveland Clinic 05 Train Next-Gen Surgeons I n v e s t o r P r e s e n t a t i o n
212 0 2 6 / / Catalysts & Pipeline Enabling Technologies Scoliosis • Orthex surgical software • Firefly patient-specific planning/guides • 7D spinal interoperative navigation • PediPortal app • Medtech Concepts – Acquired May 1, 2023 • Advancing non-fusion treatment • Early-onset scoliosis innovations • Innovation in highly-complex fusion • Manual growing, rib based, etc. • Custom Scoliosis Bracing T&D • Expanding intramedullary nailing portfolio • Expanding of external fixation portfolio • Expanding specialty bracing portfolio • Solutions for rare bone disease
222 0 2 6 / / New Growth from Current Gaps in Product Offering 3P | Hip 3P | Mini 2.0 / 2.4 / 2.7 / 3.5 Screw System 3P | Tibia 3P | Femur
232 0 2 6 / / eLLi Verteglide • Launched in January 2024 • Focus on chest wall expansion to improve breathing capacity • Sets the stage for future growth-friendly implants • Launched in August 2025 • Guided Growth • Allows for screws to “glide” along smooth rods • Harnessing the child’s growth to gradually correct the spine • Minimizes wear debris concerns • FDA submission expected by early 2026 • Electromechanical Lengthening Implant • External control module “talks” to implant • Delivers precise commands for power and distance • Addresses concerns of previous growing rods VerteGlideTM eLLiTM Rib & Pelvic System Building an EOS Platform
242 0 2 6 / / OPSB Key Growth-Strategic Objectives Aggressive market-based clinic expansion strategy Accelerate R&D with increasing number of YoY launches Scale OPSB selling channel and sales force – grow with current portfolio of products Launch 4 products in 2024 and 5 in 2025 18 new markets by 2027 (27 total) Doubling size of the sales channel
252 0 2 6 / / OPSB Market Expansion Pace of Market Expansion +4 markets in 2025 +6 markets in 2026 +8 markets in 2027 OPSB clinics expected to be in 27 territories in 2027 out of 80 target territories
262 0 2 6 / / OPSB ROI and Timing for Clinic Expansion 1-4 Clinics per market expected Acqui-HireGreenfield $500K-$1M$200k-$500kInitial Investment Positive EBITDA by end of first full year Positive EBITDA by end of first full yearEBITDA Goal Within first yearAfter first full yearFCF Goal Break even ROI by Year 5Break even ROI by Year 3ROI Goal Immediate licensure, insurance, location, clinicians, training etc. 6 months for licensure, insurance, lease, clinicians, training, etc. Time to Ramp 25%40%IRR 5
272 0 2 6 / / Trauma & Deformity +19% CAGR 14 68 2016 2025 $26.8 $166.3 2016 2025 Pediatric Systems Revenue +22% CAGR Scoliosis >4X Growth 3 17 2016 2025 $9.3 $66.0 2016 2025 Pediatric Systems Revenue >6X Growth 2025 Revenue by Product Family Trauma & Deformity Scoliosis Sports Medicine70% of Revenue 28% of Revenue >85 Differentiated Pediatric Systems Driving Growth
282 0 2 6 / / $0.6 $3.0 $7.1 $10.2 $16.1 $19.6 $23.7 $31.0 $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 $264.0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Strong History of Y/Y Growth ($M) 400% 137% 44% 58% 22% 21% 31% 20% 22% 26% 26% -2% 38% U.S. International 1 25% 1 Impacted by COVID 22% 38% 2 Represents the midpoint of the Company’s 2026 revenue guidance range of $262.0 to $266.0 million 15% 2 12%
292 0 2 6 / / $19.3 $22.5 $26.8 $32.8 $39.7 $49.4 $47.7 $65.8 $85.1 $106.8 $145.1 $166.3 $3.6 $7.4 $9.4 $11.6 $16.7 $21.5 $20.7 $28.0 $33.4 $37.9 $55.2 $66.0 $0.8 $1.1 $1.1 $1.2 $1.2 $1.7 $2.7 $4.2 $3.8 $4.0 $4.4 $4.0 $0 $50 $100 $150 $200 $250 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Re ve nu e ($ in M ill io ns ) Trauma & Deformity Scoliosis Sports Medicine/Other $37.9 $41.7 $44.1 $42.6 $13.6 $18.5 $16.3 $17.6 $0.9 $0.9 $0.8 $1.4 1Q25 2Q25 3Q25 4Q25 Category Revenue Summary 1 1 Impacted by COVID
302 0 2 6 / / Seasonality Drives Stronger Performance in Summer Months and Holiday Periods 22% 27% 26% 25% 19% 27% 29% 25% 21% 27% 27% 25% 22% 26% 27% 26% 22% 26% 26% 26% 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Re ve nu e as % o f T ot al Y ea r 2021 2022 2023 Revenue Seasonality 2024 2025
312 0 2 6 / / FY2025FY2024FY2023 $236.3$204.7$148.7Revenue 15%38%22%Growth % $172.7$148.6$111.3Gross profit 73%73%75%Margin % $211.9$183.6$138.0Operating expenses ($39.2)($35.0)($26.8)Operating loss ($39.6)($37.8)($21.0)Net (loss) income ($1.69)($1.64)($0.92)EPS diluted Income Statement Summary ($ in Millions) 4Q 20254Q 2024 $61.6$52.7 17%40% $45.1$35.6 73%68% $53.3$49.6 ($8.2)($14.1) ($10.1)($16.1) ($0.43)($0.69)
322 0 2 6 / / Revenue By Geography and Product Category Twelve Months Ended December 31, Three Months Ended December 31, 2025202420252024Product Sales by geography $186.4$161.2$48.6$42.9U.S. 49.943.513.09.8International $236.3$204.7$61.6$52.7Total Revenue Twelve Months Ended December 31, Three Months Ended December 31, 2025202420252024Product Sales by category $166.3$145.1$42.6$36.4Trauma and deformity 66.055.217.615.6Scoliosis 4.04.41.40.6Sports medicine/other $236.3$204.7$61.6$52.7Total Revenue ($ in Millions)
332 0 2 6 / / Adjusted EBITDA Reconciliation Twelve Months Ended December 31, Three Months Ended December 31, 2025202420252024 ($39.6)($37.8)($10.1)($16.1)Net loss 6.02.61.91.3Interest expense, net (6.0)1.1(0.3)1.0Other expense (income), net 0.5(4.1)0.3(0.3)Income tax benefit 21.219.15.74.0Depreciation and amortization 4.61.82.41.8Intangible asset impairment 16.413.53.13.9Stock-based compensation 5.63.60.33.7Restructuring charges 1.4-0.4-Tariffs 0.11.4-1.4 European Union Medical Device Regulation fees 4.32.31.71.8Acquisition related costs -3.2--MidCap financing termination fees 0.31.8(0.6)0.6Minimum purchase commitment cost $14.8$8.5$4.8$3.0Adjusted EBITDA ($ in Millions)
342 0 2 6 / / Adjusted EPS Reconciliation Twelve Months Ended December 31, Three Months Ended December 31, 2025202420252024 ($1.69)($1.64)($0.43)($0.69)Loss per share, diluted (GAAP) -0.02-- Accretion of interest attributable to acquisition installment payment 0.200.080.100.08Intangible asset impairment 0.240.160.010.16Restructuring charges 0.06-0.02-Tariffs -0.06-0.06European Union Medical Device Regulation fees 0.180.100.070.08Acquisition related costs -0.14--MidCap financing termination fees 0.010.08(0.03)0.02Minimum purchase commitment cost ($1.00)($1.00)($0.26)($0.29)Adjusted loss per share, diluted (non-GAAP)
352 0 2 6 / / Free Cash Flow ($M) $(11) $(15) $(10) $(6) $(8) $(13) $(3) $10 $(20) $(15) $(10) $(5) $- $5 $10 $15 1Q 2Q 3Q 4Q 2024 2025 $9 $15 $(21) $(17) $(30) $(13) ($50) ($40) ($30) ($20) ($10) $0 $10 $20 2024 2025 Cash Used For Working Capital Sets Deployed Adj. EBITDA ($42) ($15)
362 0 2 6 / / Balance Sheet Assets $62.9Cash, cash equivalents & short-term investments 53.8Account receivable 133.8Inventory (net) 5.9Other current assets 256.4Total Current Assets 49.6PP&E (net) 202.6Intangibles and goodwill $508.6Total Assets Liabilities $18.8Accounts payable 100.0Debt 38.2Accrued comp. & other liab. 5.1Acquisition pay. & cont. consideration 622.3Paid-in capital (275.2)Accumulated deficit (net) (0.5)Accumulated other comprehensive loss $508.6Total Liabilities / Equity ($ in Millions) As of December 31, 2025
372 0 2 6 / / 2026 Guidance FY2026 $262.0 to $266.0Revenue ~$25.0Adjusted EBITDA BreakevenFree Cash Flow FY2026 11% to 13%2026 Total Revenue Growth % ~$10.0Set Deployment Assumptions Full Year 2026 Guidance ($ in Millions)
382 0 2 6 / / Investment Summary Only diversified company focused exclusively on pediatric orthopedics Large, underpenetrated market opportunity in pediatrics Highly concentrated customer base with targeted commercial strategy Broad product portfolio with innovative solutions Only provider committed to pediatric clinical education Dynamic, award-winning corporate culture Proven commercial execution and attractive financial profile 01 04 02 05 03 06 07
2850 Frontier Drive Warsaw, IN 465852 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302 www.OrthoPediatrics.com2 0 2 6 / /
FAQ
How did OrthoPediatrics Corp. (KIDS) perform financially in 2025?
OrthoPediatrics generated $236.3 million in 2025 revenue, up 15% from $204.7 million in 2024. Gross profit was $172.7 million with a 73% margin, while net loss totaled $39.6 million and diluted EPS was $(1.69).
What 2026 financial guidance did OrthoPediatrics (KIDS) provide?
For 2026, OrthoPediatrics guided to $262.0–$266.0 million in revenue, implying 11–13% growth. Management targets about $25 million in Adjusted EBITDA and breakeven free cash flow, alongside roughly $10 million of instrument set deployments.
How are OrthoPediatrics’ profitability and Adjusted EBITDA trending?
The company remained unprofitable in 2025 with a $39.6 million net loss, but Adjusted EBITDA improved to $14.8 million. This compares with $8.5 million in 2024, reflecting better operating leverage as revenue grows and integration of acquired businesses progresses.
What does OrthoPediatrics’ 2025 cash flow and balance sheet look like?
Free cash flow improved significantly in 2025, with a $15 million outflow versus $42 million in 2024. As of year-end 2025, OrthoPediatrics held $62.9 million in cash, cash equivalents and short-term investments, against $100.0 million of debt and total assets of $508.6 million.
How fast has OrthoPediatrics’ revenue grown over time?
Revenue increased from $148.7 million in 2023 to $204.7 million in 2024 and $236.3 million in 2025. The presentation shows a long history of year-over-year growth and cites a roughly 20%+ compound annual revenue growth rate from 2016 through 2025.
Which product categories drive OrthoPediatrics’ revenue mix?
In 2025, trauma and deformity products delivered $166.3 million of revenue, scoliosis contributed $66.0 million, and sports medicine/other added $4.0 million. Trauma and deformity remained the largest category, accounting for the majority of company-wide sales.
What strategic growth initiatives is OrthoPediatrics (KIDS) pursuing?
The company emphasizes pediatric-focused R&D, acquisitions such as Boston Orthotics & Prosthetics, and expansion of its OPSB clinic footprint. It plans multi-year market-based clinic growth, more product launches in 2024–2025, and continued investment in enabling technologies and surgeon education.
Filing Exhibits & Attachments
5 documentsPress Releases
Orthopedia
NASDAQ:KIDS
KIDS Rankings
KIDS Latest News
KIDS Latest SEC Filings
Feb 26, 2026
[8-K] ORTHOPEDIATRICS CORP Reports Material Event
Jan 12, 2026
[8-K] ORTHOPEDIATRICS CORP Reports Material Event
Jan 12, 2026
[8-K] ORTHOPEDIATRICS CORP Reports Material Event